Skip to content
Search

Latest Stories

India's Serum Institute expects approval for AstraZeneca vaccine 'very soon'

THE Serum Institute of India, the local maker of the Oxford/AstraZeneca coronavirus vaccine, said on Monday(28) it expected the British and Indian governments to approve shots for emergency use within a few days.

"You will be hearing some good news from the UK very soon," Serum's chief executive Adar Poonawalla told reporters, adding that approval from the Indian regulator would likely follow shortly.


"By January, we should have the AstraZeneca/Oxford vaccine licensed."

The company has already made 40 million to 50 million doses of the vaccine and will be able to ramp up capacity to around 100 million a month by March when a new facility comes online, Poonawalla said.

India wants to deliver 600 million coronavirus shots in the next six to eight months starting in January. The country's drug regulator is also considering similar approvals for the Pfizer /BioNTech vaccine and another developed by India's Bharat Biotech.

Some Indian states on Monday began a trial run of Covid-19 vaccine delivery systems, with health authorities checking everything from their technology platforms to the storage infrastructure that will be required to inoculate millions.

"The exercise is basically a mock drill for our healthcare workers on how to run the whole vaccination process and system," said Jaiprakash Shivahare, the commissioner for health in the western state of Gujarat.

State health officials had set up 19 vaccination centres, each with 25 dummy beneficiaries played by health workers, who would help test out the entire inoculation sequence, including online monitoring systems, Shivahare said.

"The cold chain infrastructure for distribution of the vaccine is also being tested as a part of the dry run," he said.

India has the second-highest number of confirmed coronavirus cases in the world after the United States, and it has recorded 147,901 deaths so far.

On Monday, the federal health ministry reported a daily increase of a little over 20,000 infections, taking the country's total so far to 10.2 million cases.

More For You

Shefali Jariwala

Glutathione and anti ageing drugs under spotlight after Shefali Jariwala death

Instagram/shefalijariwala

Did anti-ageing pills, beauty supplements and glutathione trigger Shefali Jariwala’s death?

Quick highlights:

  • Shefali Jariwala died at 42 in Mumbai after reportedly collapsing post-fast; cause of death suspected to be cardiac arrest or blood pressure drop.
  • Police found anti-ageing pills, vitamin supplements, and glutathione injections at her residence.
  • Doctors stress the risks of unsupervised use of hormone-based and anti-ageing treatments.
  • Final post-mortem report expected in two days; no foul play suspected, case treated as accidental death.

The untimely death of actor-model Shefali Jariwala has sparked renewed concern over the unregulated use of anti-ageing treatments and self-medication. The 42-year-old, best known for her appearance in Kaanta Laga, was declared dead on arrival at a Mumbai hospital on Friday night. Initial investigations suggest she may have suffered a cardiac arrest following a steep drop in blood pressure, possibly linked to taking supplements on an empty stomach.

Keep ReadingShow less
Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less